



20 November 2023

ASX Announcement

## **SHAREHOLDER TOWN HALL WEBINAR**

InhaleRx Ltd (ASX: IRX), (“**InhaleRx**”, “**IRX**” or “**the Company**”) an Australian healthcare company developing unique inhaled medicinal drug-device products to address unmet medical needs in pain management and mental health sectors, is pleased to invite shareholders to a webinar on Wednesday, 22 November 2023, commencing at 12pm AEDT.

The webinar will provide an update on progress with the Company’s clinical development program.

To access the webinar, please use the following link:

[https://us02web.zoom.us/webinar/register/WN\\_TuXVq1hDTEuMDTIhtrtgZw](https://us02web.zoom.us/webinar/register/WN_TuXVq1hDTEuMDTIhtrtgZw)

Shareholders are encouraged to email any specific questions they would like addressed by 5pm AEDT on Tuesday, 21 November 2023 to: [info@inhalerx.com.au](mailto:info@inhalerx.com.au)

Those shareholders who are unable to attend are similarly encouraged to email their question by the above closing date and time.

A copy of the presentation slides for the webinar will be lodged on the ASX immediately prior to the webinar commencing.

Authorised by the Board of Directors.

### **For further information:**

James Barrie  
Company Secretary  
Phone +61 3 8678 4091  
[info@inhalerx.com.au](mailto:info@inhalerx.com.au)  
[www.inhalerx.com.au](http://www.inhalerx.com.au)

**About InhaleRx Limited (ASX: IRX) – [www.inhalerx.com.au](http://www.inhalerx.com.au)**

InhaleRx Limited (ASX: IRX) (“InhaleRx” or “the Company”) is an Australian healthcare company which is developing unique medicinal drug-device products to address unmet medical needs in pain management and mental health sectors.

The overarching goal is to pursue U.S. FDA approval and registration to treat Panic Disorder and pain using rapid and cost effective regulatory pathways, such as 505(b)(2). A 505(b)(2) application is a New Drug Approval (NDA) that contains full reports of investigations of safety and effectiveness, where at least some of the information required for approval comes from studies available in the public domain.

There is a significant economic opportunity for InhaleRx and the Company’s shareholders as these carefully selected medical indications under investigation currently have extremely limited treatment options, whilst also offering a low side effect profile.

InhaleRx holds an innovation patent and provisional patents for the nominated indications and the company plans to continue to strengthen this position.